Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Journal Title: Journal of Cancer and Tumor International - Year 2016, Vol 3, Issue 1
Abstract
Aims: Advanced Hepatocellular carcinoma (HCC) is a major health problem with limited treatment options. The Sorafenib monothearpy is the only efficacious systemic treatment agent showing a survival benefit in these patients. In our study, we evaluated the efficacy and tolerability of Sorafenib in advanced and metastatic HCC patients. Methodology: Twenty patients with advanced HCC (between Jan. 2011 and Dec. 2013), and not eligible for loco regional therapy were treated prospectively with Sorafenib monotherapy with assessment of survival and toxicity. Follow up was until Oct. 2014. Results: According to Eastern Cooperative On¬cology Group (ECOG) performance status (PS) of 2 was found in the most of patients 13/20 while Ps 3 in 7/20 and Child-Pugh class A in (40.0%) of cases and B (60.0%) of patients. Six patients had stage IV-A tumors, whereas 14 had stage IV-B tumors. Four patients had portal vein tumor thrombosis (PVTT). Following Sorafenib monotherapy, the disease control rate was( 65.0)% with 5 patients (25.0%) had a parial response while stable disease in 8 patients (40.0%) with a median overall survival of 12 months and the median progression-free survival was 0 months. Diarrhea and hand-foot skin reactions were the major side effects. Conclusions: In our study, the use of Sorafenib monotherapy in the patients with advanced HCC showed a reasonable outcome and was well tolerated. Further study with a larger number of patients and treated with a long duration is warranted.
Authors and Affiliations
Yasser M. Saleh, Waleed Hammam
Keywords
Related Articles
- EP ID EP242952
- DOI 10.9734/JCTI/2016/22142
- Views 114
- Downloads 0
Association between Age, Tumour Location and Survival of Patients in Morocco
Aims: Cancer is a major burden of disease worldwide. Each year, tens of millions of people are diagnosed with cancer around the world, and more than half of the patients eventually die from it. The present work aims to b...
Histopathological Pattern of Pediatric Malignant Tumors and Survival Rate at Kilimanjaro Christian Medical Centre, Tanzania from 2013 to 2015
Background: Childhood malignant tumors are among diseases that cause death to children below 14 years. Although it is the second most common cause of death in children in developed countries, its magnitude in Africa is n...
Differential Expression of Claudin-1, Claudin-3, and Claudin-4 in Bladder Lesions
Aims: Claudins are major transmembrane proteins of tight junctions. As the disruption of their function have important impact on tumorogenesis, invasion and metastasis. Claudins became a focus of interest for targeting t...
Consequences of Altered Body Image in Adolescents with Cancer: A Narrative Review
Background: The diagnosis of cancer develops many challenges for adolescents. Changes associated with cancer treatment are considered stressful and impact negatively on adolescents' psychosocial status. Adaptation to bod...
Intracranial Hemangiopericytoma in a 15 Year-old Child: Neuroimaging Features and Management Therapy
Introduction: Intracranial hemangiopericytoma (HPR) is a highly vascular tumors which is exceptional in children. They may present management difficulties in some cases. Clinical Presentation: The authors report the case...